Evidence map›Paper›PMID 32803196›Full record

ArticlebioRxiv : the preprint server for biology2020

Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.

Wei Zhu, Miao Xu, Catherine Z Chen, Hui Guo, Min Shen, Xin Hu, Paul Shinn, Carleen Klumpp-Thomas, Samuel G Michael, Wei Zheng

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 27 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Wei ZhuNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA.
Miao XuNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA.
Catherine Z ChenNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA.
Hui GuoNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA.
Min ShenNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA.
Xin HuNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA.
Paul ShinnNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA.
Carleen Klumpp-ThomasNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA.
Samuel G MichaelNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA.
Wei ZhengNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20850, USA.
National Institutes of Health · US

Funding

Drug Repurposing Screening for Rare and Neglected DiseasesZIATR000018 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI ZHENG, WEI · 2015 to 2025
$24.6M
COVID-19: Identification and Development of Clinical Candidates to Treat SARS-CoV-2 ZIATR000422 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI LO, DONALD · 2020 to 2021
$3.3M
6 · The paper itself

Abstract

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emphasized the urgency to develop effective therapeutics. Drug repurposing screening is regarded as one of the most practical and rapid approaches for the discovery of such therapeutics. The 3C like protease (3CL

Identifiers

PMID32803196
PMCPMC7427131
OpenAlexW3043120694

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.